Description General description A cell-permeable, potent and selective inhibitor of nitric oxide (NO)-sensitive guanylyl cyclase (IC50 = 20 nM). In incubated cerebellum slices, ODQ reversibly inhibits the NO-dependent cGMP response to glutamate receptor agonists without affecting NOS activity. It does not chemically inactivate NO; however, it does inhibit cGMP generation in response to NO donors. ODQ does not inhibit NO-mediated macrophage toxicity, a phenomenon unrelated to cGMP, nor does it affect the activity of particulate guanylyl cyclase or adenylyl cyclase. A potent and selective inhibitor of nitric oxide (NO)-sensitive guanylyl cyclase (IC50 = 20 nM). In incubated cerebellum slices, ODQ reversibly inhibits the NO-dependent cGMP response to glutamate receptor agonists without affecting NOS activity. It does not chemically inactivate NO; however, it does inhibit cGMP generation in response to NO donors. ODQ fails to inhibit NO-mediated macrophage toxicity, a phenomenon unrelated to cGMP, nor does it affect the activity of particulate guanylyl cyclase or adenylyl cyclase. Packaging 10 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: yes Primary Target (NO)-sensitive guanylyl cyclase Product does not compete with ATP. Reversible: yes Target IC50: 20 nM against nitric oxide (NO)-sensitive guanylyl cyclase Warning Toxicity: Irritant (B) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C. Other Notes Wang, D., et al. 1998. J. Biol. Chem. 273, 33027. Southam, E., et al. 1996. Br. J. Pharmacol. 119, 527. Brunner, F., et al. 1995. FEBS Lett.376, 262. Garthwaite, J., et al. 1995. Mol. Pharmacol.48, 184.